Discovery Life Sciences and Mindpeak have come together to integrate Artificial Intelligence (A)-powered digital pathology into cancer biomarker testing for global clinical trials, aiming to reduce variability in biomarker interpretation and improve confidence in critical drug development decisions. The collaboration aims to support biopharma R&D and clinical research by improving biomarker quantification and inter-reader concordance, helping to reduce variability, de-risk biomarker-driven trials and strengthen confidence in critical development decisions.

The partnership couples Mindpeak's AI platform with Discovery's tissue biomarker services to analyse IHC and mIF slides. Mindpeak's technology acts as a safeguarding tool for biopharma, reducing risks in biomarker development by improving consistency in interpretation across pathologists. It includes AI-enabled pathology workflows, pathologist training via Mindpeak's peakAcademy, and AI-guided microdissection algorithms to isolate specific tissue regions with high accuracy.

Discovery brings significant clinical infrastructure to the alliance. Its Biomarker Academy, a peer-to-peer pathologist training programme established in 2008, has trained more than 6,000 pathologists in biomarker interpretation and scoring over the past 15 years.

Discovery has supported over 2,000 clinical trial programmes, with 350 currently active, and has completed over 35 IVDR-compliant studies across 16 European Union (EU) countries involving 25 biomarkers in the past four years. This partnership extends Discovery's AI advancements, building on existing H&E-focused AI solutions for biospecimen analysis, including automated quality control, tumour quantification and detailed tumour microenvironment characterisation across various therapeutic areas.

"As AI use in pathology increases for clinical research, this partnership with Mindpeak allows integration of modeling tools that can enable improved accuracy in biomarker analysis. Combining these AI capabilities with our clinical trials expertise will help assist in advancing the development of biomarker-focused therapies," said Greg Herrema, CEO, Discovery Life Sciences.

The Mindpeak and Discovery alliance aims to streamline trial processes and enhance data reproducibility in regulated settings, supporting more confident decisions in patient stratification and therapeutic development.

"This collaboration with Discovery Life Sciences provides access to our AI platform, training and micro-dissection tools, supporting researchers in IHC and mIF applications and helping to drive greater consistency and confidence in biomarker assessment," said Felix Faber, Founder and CEO, Mindpeak.

Additional details on the partnership and use cases will be presented at the AACR Annual Meeting 2026.